FDA Clears Viral Therapy for Treatment-Resistant Melanoma
WASHINGTON, D.C. — The U.S. Food and Drug Administration granted accelerated approval to Replimune Inc.’s Tudriqev in combination with nivolumab for adults with unresectable advanced melanoma that progressed after PD-1-based …
FDA Clears Viral Therapy for Treatment-Resistant Melanoma Read More